Clinical trial

APG-2449 in Patients With Advanced Solid Tumors

NCT03917043

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2019-05-27

PhasePHASE1

Study timeline

Study start (actual)2019-05-27Date precision: day

Registry last updated2026-07-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Solid Cancerunresolved

Non Small Cell Lung Cancerunresolved

Esophageal Cancerunresolved

Ovarian Cancerunresolved

Malignant Pleural Mesotheliomaunresolved

Interventions

Sponsors & collaborators

Ascentage Pharma Group Inc.lead sponsor

Suzhou Yasheng Pharmaceutical Co., Ltd.collaborator

Mapped research locations

GuangzhouGuangdong, China2 FuzhouFujian, China2 BeijingBeijing Municipality, China1 HangzhouZhejiang, China1 ChangshaHunan, China1 WuhanHubei, China1 ZhengzhouHenan, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03917043 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.